If you're in biotech, immunology, or drug development - this is the episode you’ve been waiting for.

We’re joined by Dr. Bhaskar Srivastava, Chief Medical Officer at Triveni Bio, whose career has spanned over 10 years across J&J, Nimbus, and now Triveni Bio, one of the most ambitious autoimmune biotech startups on the scene.

In this episode, Bhaskar dives deep into:

· How Triveni is building a first-in-class pipeline targeting the kallikrein system - a bold bet to treat severe skin and inflammatory conditions by tackling novel biology.

· What it means to be a founder’s CMO, and how great science needs the right development strategy to make a difference.

· Candid stories from his past roles at Nimbus (which sold its TYK2 program to Takeda for $4B) and Janssen, where he helped guide first-in-class therapies from Phase 1 to pivotal trials.

· Why bispecifics may be risky but worth it, and how Triveni is using novel biologics to crack tough diseases like atopic dermatitis.

· Advice for executives: how to balance ambition and discipline, when to say no, and why choosing the right team members matters as much as the science.

🎙 Bhaskar doesn’t just talk science - he connects molecular biology to patient need, clinical strategy, and company vision with clarity and purpose.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Bhaskar Srivastava

CMO at Triveni Bio

LinkedIn: https://www.linkedin.com/in/bhaskar-srivastava-355a9ab1/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Career Beginnings

15:44 Success & Growth in Biotech

28:43 Investing in Biotech

34:23 The Future of Dermatology & Triveni Bio

#LeadingBeyondTheLab #ARTOTalent #Biotechnology 

Hosted on Acast. See acast.com/privacy for more information.